Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Apr;5(7):166.
doi: 10.21037/atm.2017.03.55.

The KEY to the end of chemotherapy in non-small cell lung cancer?

Yiqing Huang  1 , Ross A Soo  1   2   3
Affiliations
Editorial

The KEY to the end of chemotherapy in non-small cell lung cancer?

Yiqing Huang et al. Ann Transl Med. 2017 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: RAS has received honorarium from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho; and research funding from AstraZeneca. YH has no conflict of interest of interest to declare.

Comment on

  • Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Reck M, et al. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718847 Clinical Trial.

References

    1. Mok TS, Wu Y, Thongprasert S, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
    1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non–small cell lung cancer. N Engl J Med 2014;371:1963-71. 10.1056/NEJMoa1406766 - DOI - PMC - PubMed
    1. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415-26. 10.1016/S0140-6736(16)00004-0 - DOI - PubMed
    1. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-v27. 10.1093/annonc/mdw326 - DOI - PubMed

LinkOut - more resources